Evofem Biosciences (EVFM) Q3 2024 earnings summary

Executive summary

• Evofem Biosciences focuses on commercializing Phexxi, a non-hormonal contraceptive gel, and recently acquired global rights to SOLOSEC, an FDA-approved antimicrobial for BV and trichomoniasis.

• Phexxi net sales have grown each year since launch in 2020; 2024 growth drivers include expanded use among women on GLP-1 medications.

• The company is pursuing global expansion via licensing, with recent deals in the Middle East and regulatory submissions in multiple countries, including the UAE.

• A merger with Aditxt is pending, with several amendments to the agreement and ongoing support from key investors.

• Launched a collaboration with Pearsanta for a blood-based endometriosis diagnostic test.

Financial highlights

• Net product sales for Q3 2024 were $4.5M, down 12% year-over-year due to lower unit sales, partially offset by a price increase.

• Q3 2024 net loss attributable to common stockholders was $2.4M, or $0.02 per share, compared to net income of $66.0M in Q3 2023 (which included a $75.3M gain on debt extinguishment).

• Operating expenses for Q3 2024 decreased across all categories, with a 20% reduction overall and a 54% decrease in cost of goods sold year-over-year.

• Cash and cash equivalents as of September 30, 2024 were $0.7M, with a working capital deficit of $67.7M and an accumulated deficit of $894.6M.

• Total liabilities increased to $90.1M as of September 30, 2024, up from $72.5M at year-end 2023.

Outlook and guidance

• Management expects continued net losses and negative cash flows for the foreseeable future; current liquidity is insufficient for the next 12 months.

• Plans to meet cash needs include revenue growth from Phexxi and SOLOSEC, restructuring payables, and raising additional capital through equity, debt, or partnerships.

• The company is working toward closing the Aditxt merger in 2025, subject to shareholder approval and multiple closing conditions.

• Regulatory submission for Phexxi in the UAE is on track for year-end 2024.